[Edaily Reporter PARK JONG-HWA ] DB INSURANCE announced that it will increase its annual dividend per share by at least 10% to enhance shareholder value. DB INSURANCE headquarters.
DB Inc. disclosed a mid- to long-term corporate value enhancement plan containing these details on the 28th. In the disclosure, DB Inc. set a goal to raise its shareholder return ratio (the proportion of net income returned to shareholders through cash dividends, share buybacks, and cancellations) to 40% on a consolidated basis and 50% on a standalone basis by 2030. To achieve this, the company decided to increase its dividend per share by at least 10% annually.
In addition, the company plans to manage the “sustainability of dividends” by introducing the DCR (Dividend Coverage Ratio), calculated by dividing distributable earnings by the projected dividend amount. The company’s policy is to implement additional returns to shareholders if ROE (Return on Equity) falls below COE (Cost of Equity) or if both the K-ICS (Korean Insurance Solvency Ratio) of 220% and the DCR of 400% are exceeded simultaneously. In addition, it has set K-ICS at 180% and DCR at 200% as safety thresholds to ensure both capital adequacy and dividend funding.
In this disclosure, DB Insurance also announced plans to cultivate Potegra, a U.S. insurance group acquired last year, as a global growth engine. Potegra has maintained its growth momentum, achieving an average annual revenue growth rate of 14.7% over the past five years.
Nam Seung-hyung, Chief Financial Officer (CFO) of DB Insurance, stated, “Shareholder value should not be a byproduct of management but rather the starting point for decisions regarding growth and capital allocation.” He added, “We will execute our plans based on sustainable performance rather than short-term expansion, so that we can meet shareholder expectations while maintaining policyholders’ trust.”
SamsungElectronics hosted “SPARK 2026,” an integrated industry-academia exchange event, to broaden its industry-academia collaboration with domestic universities and jointly explore future directions …
SANIGEN Co., Ltd.(188260), a company specializing in genome-based microbial diagnosis and control, has announced its leap toward becoming a global innovative biopharmaceutical company, spearheaded by …
VUNO, Inc.(338220)announced on the 28th that it has decided to conduct a rights offering worth 31.4 billion won. VUNO, Inc. plans to issue 6.3 million new common shares at 4,980 won per share (planned…